Entyvio Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Entyvio market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period was driven by the rising prevalence of inflammatory bowel disease, increased awareness of biologic therapies, broader applications of vedolizumab, a preference for gut-selective treatments, and higher healthcare expenditure.

In the forecast period, growth is expected to be fueled by approvals for subcutaneous formulations, increased adoption of maintenance therapy, favorable clinical guidelines, minimal systemic immunosuppression, and supportive insurance and reimbursement policies. Key trends anticipated during this period include advancements in the drug pipeline, technological innovations, product developments, strategic collaborations, and rising investments.

The rising incidence of inflammatory bowel disease (IBD) is anticipated to drive the growth of the entyvio market. IBD encompasses chronic, relapsing inflammatory disorders of the gastrointestinal (GI) tract caused by immune system dysregulation, resulting in prolonged inflammation and tissue damage. The increasing prevalence of IBD is attributed to factors such as genetic predisposition, environmental changes like diet and urbanization, lifestyle stress, and gut microbiota alterations influenced by antibiotics and reduced exposure to natural microbes. Entyvio addresses IBD by targeting and blocking the alpha4beta7 integrin, reducing the migration of inflammatory cells to the gut. For example, in June 2024, the U.S.-based Centers for Disease Control and Prevention (CDC) estimated that 2.4 to 3.1 million individuals in the U.S. are affected by IBD. This rising prevalence significantly contributes to the expansion of the entyvio market.

An increase in healthcare expenditure is expected to boost the growth of the entyvio market. Healthcare expenditure represents the total financial resources allocated to health services and goods to enhance individual and population health. This growth is driven by factors like the rising prevalence of chronic diseases, medical technology advancements, an aging population requiring intensive care, increased costs of prescription drugs and specialized treatments, and expanded access to healthcare in developed and developing regions. Higher healthcare spending supports Entyvio by improving access to advanced biologic therapies for conditions like Crohn's disease and ulcerative colitis, funding research, development, and distribution, and integrating these therapies into treatment protocols. For instance, in May 2023, the UK’s Office for National Statistics reported a 5.6% increase in healthcare spending between 2022 and 2023, totaling $317.63 billion (£292 billion) in 2023. This rise underscores the importance of healthcare investment in driving the entyvio market's growth.

A significant trend in the Entyvio market is the development of maintenance therapies for long-term management of IBD. Maintenance therapies aim to manage chronic conditions, prevent disease progression, and sustain stable or improved health after achieving initial treatment goals. These therapies help reduce relapses and complications, ensuring sustained disease control and better patient quality of life. For instance, in April 2024, Takeda Pharmaceuticals, a U.S.-based pharmaceutical company, received FDA approval for subcutaneous (SC) administration of Entyvio for maintenance therapy in adults with moderate to severe Crohn's disease following induction therapy with intravenous (IV) Entyvio. The SC option allows patients to self-administer the medication using a pre-filled pen, enhancing convenience and enabling at-home treatment after the initial IV induction phase. Clinical studies have demonstrated Entyvio’s effectiveness in improving symptoms and inducing remission in Crohn’s disease patients, reinforcing its value in maintenance therapy.

Key player operating in the entyvio market is Takeda Pharmaceutical Company Limited.

North America was the largest region in the Entyvio market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in entyvio report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the entyvio market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Entyvio (vedolizumab) is a monoclonal antibody medication that acts as an integrin receptor antagonist. It works by preventing inflammatory white blood cells from entering the gastrointestinal tract, thereby reducing inflammation and managing symptoms associated with these conditions.

In the entyvio market, the primary administration methods are subcutaneous injection and intravenous infusion. The subcutaneous injection formulation enables patients to self-administer the medication at home. Treatment options include first-line and second-line therapies, with indications such as ulcerative colitis (UC) and Crohn's disease (CD). These are utilized across various end-user settings, including hospitals, clinics, ambulatory care, and home care.

The entyvio market research report is one of a series of new reports that provides entyvio market statistics, including Entyvio industry global market size, regional shares, competitors with a entyvio market share, detailed entyvio market segments, market trends, and opportunities, and any further data you may need to thrive in the entyvio industry. This entyvio market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The entyvio market consists of sales of induction therapy and maintenance therapy. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.